Amgen: A Biotech Bargain Heading Into Q3 Earnings

Amgen is scheduled to report Q3 results on November 3. Its Q2 non-GAAP EPS rose 25.8% quarter-on-quarter to $6.29, primarily on strong performance from biosimilars, Blincyto, and Repatha; the company also reported promising DeLLphi-305 study results for Imdelltra plus Imfinzi in extensive-stage small-cell lung cancer.

Analysis

The setup is event-driven, but the sequential EPS jump is a weak basis for extrapolating earnings power: mix, timing, and any nonrecurring items can make quarter-on-quarter growth look stronger than the underlying run rate. The key Q3 read-through is whether biosimilar growth and newer-product demand translate into durable revenue and margin contribution, rather than merely favorable quarterly mix. Verify product-level sales, gross-margin direction, and full-year guidance against consensus before assigning an earnings multiple to the recent acceleration.

The DeLLphi-305 update could improve the strategic value of Amgen’s oncology asset and create a complementary opportunity for AstraZeneca if the combination proves clinically and commercially viable. But “promising” alone does not establish effect size, safety, regulatory relevance, or commercial economics; the investment case remains conditional on full study details and subsequent regulatory milestones. Competitive impact on existing small-cell lung cancer regimens is therefore a medium-term possibility, not a near-term revenue catalyst.

Over the next days, the November 3 report and guidance dominate price risk. Over 1–3 months, product-level growth, trial detail, and follow-up data matter more than headline EPS. Over 6–18 months, the combination’s clinical differentiation and launch execution determine whether it changes the oncology growth profile. The positive framing may be undercut if Q3 guidance fails to validate recurring growth; without consensus, valuation, and options-implied move data, there is no clear risk-adjusted directional trade.

Key Decisions for Investors

• Treat AMGN as an earnings event, not a momentum buy based on sequential EPS growth. Before positioning, compare Q3 consensus with product-level sales, margin trends, and full-year guidance; a guidance cut or evidence that growth is mainly mix/timing would falsify the constructive view.
• Keep the DeLLphi-305 news on the catalyst watchlist for AMGN and AZN, but do not capitalize it as near-term revenue. Verify endpoint magnitude, safety, study design, regulatory implications, and commercial rights/economics when disclosed.
• Avoid initiating a pre-report options position without checking implied volatility versus AMGN’s historical earnings moves and the expected move. If implied volatility is elevated, reassess after results rather than paying for an unverified clinical and earnings narrative.